Analysis of actual results of drug supply implementation within framework of High-Cost Nosologies Program

The accessibility and pharmaceutical care coverage are linked to political, economic and managerial decisions. That fact necessitates the evaluation of the state programs results in the field of the drug provision.

The aim of the work was to assess the quantitative results of the implementation of the High-Cost Nosologies program in the Russian Federation from 2008 to 2023 to determine further vectors of its improvement.

Materials and methods. The regulatory base of the work was made up of the Russian Federation legislation in the field of the drug provision. The open sources were used as the research information base for the data collection and analysis: reports of federal and regional executive authorities, materials of specialized conferences, results of published studies.

Results. The drug coverage under the High-Cost Nosologies (VZN) program is provided for 14 nosologies, 11 of which are classified as orphan diseases. Since its implementation, the HCNs program has been expanded twice by including new nosologies in 2019 and 2020. As of 01 October 2023, the number of patients in the Federal Register of VZN was 263 721 people, which was 13.58 times greater compared to 2008. The drug provision is carried out according to the list of 47 INNs. The amount of funding for the program increased from RUB 32 bn in 2008 to RUB 87.96 bn in 2023. The most resource-intensive nosologies include hemophilia, multiple sclerosis and oncohematology.

Conclusion. The main quantitative characteristics of the implementation of the HCNs program and the identified vectors for its further improvement have been analyzed in this study. The results obtained can be used to conduct analytical studies, including the ones within nosologies and nosological groups included in the program, in order to optimize a pharmaceutical care. The focus of improving the implementation of the VZN program is related to the improvement of the legal framework, a patient treatment paradigm and approaches to its financing.

1. Miladinov G. Socioeconomic development and life expectancy relationship: evidence from the EU accession candidate countries. Genus. 2020;76(2). DOI: 10.1186/s41118-019-0071-0

2. Collin ME, Weil DN. The effect of increasing human capital investment on economic growth and poverty: A simulation exercise (September 25, 2018). World Bank Policy Research Working Paper No. 8590.

3. Romanova AS. Human capital in the system of sustainable development. Proceedings BSTU. Economics and Management. 2015;7(180):310–5. Russian

4. Bezrukov NS, Polyanskaya EV. [Economic assessment of public health losses as a factor in the development of human capital]. Bulletin of the Pacific State University. 2009;1(12):57–64. Russian

5. Shafi R, Fatima S. Relationship between GDP, life expectancy, and growth rate of G7 countries. Int J Sci. 2019;8(06):74–9. DOI: 10.18483/ijSci.2085

6. Ivakhnenko OI, Avksentyeva MV, Maksimova LV. Methods for estimating indirect costs in health technology assessment. Medical technologies. Evaluation and selection. 2013;1(11):29–35. Russian

7. Avksentyeva MV, Gerasimova KV, Zheleznyakova IA, Zuev AV, Ivakhnenko OI, Ignatieva VI, Lazareva ML, Lemeshko VA, Lukyantseva DV, Melnikova LS, Musina NZ, Sura MV, Sukhorukikh OA, Fedyaev DV. [System of medical care in the Russian Federation: information bulletin]. Omelyanovsky VV, editor. Moscow: Academic Scientific Publishing, Production, Printing and Book Distribution Center “Science”; 2019. 181 p. Russian

8. Tsomartova FV. Health Protection in the Focus of Medical Legislation. Journal of Russian Law. 2021;25(8):156–60. DOI: 10.12737/jrl.2021.106. Russian

9. Shamanina EA, Polozova DV. Main principles of social and economic policy efficiency evaluation in the health system of the Russian Federation. Vestnik Akademii. 2019;(4):96–104. Russian

10. Tsomartova FV. State guarantees of availability of drugs in Russia and abroad. Journal of Foreign Legislation and Comparative Law. 2018;4(71):161–70. DOI: 10.12737/art.2018.4.21. Russian

11. Bessarab NS. Right to medical aid and medical support. Izvestiya Tula State University. Economic and legal sciences. 2019;(2):90–4. Russian

12. Kazarina ON. On the implementation of economic policy in the field of preferential drug provision of the population in the territory of the Russian Federation. Vestnik RUK. 2023;1(51):38–43. Russian

13. Vorobyev PA, Krasnova LS, Vorobyev AP, Zykova AB, Zhulyov YuA, Zozulya NI. Epidemiology, economics and quality of life of patients with hemophilia in Russia for 2007–2017: Results of standardization use in therapy. Problems of standardization in healthcare.2018;9-10:15–34. Russian

14. Telnova EA, Zagoruychenko AA. About the state of preferred medicinal provision. Bulletin of Semashko National Research Institute of Public Health. 2021;(2):72–81. DOI: 10.25742/NRIPH.2021.02.009. Russian

15. Telnova EA. Extensive drug coverage – ONLS program is 10 years. Vestnik of Roszdravnadzor. 2016;(5):143–7. Russian

16. Reykhtman TV, Moshkova LV. The approaches to maintain the availability of pharmaceutical assistance to certain categories of citizens of the Russian Federation. Research Result. Medicine and Pharmacy Series. 2014;1(2):26–37. DOI: 10.18413/2313-8955-2014-1-2-26-37. Russian

17. Tolkushin AG, Fedorov AA, Zhulev UA, Pogudina NL, Ermolaeva TN. Directions of development of the program of drug provision for expensive diseases. Health care of the Russian Federation. 2019;63(5):237–44. DOI: 10.18821/0044-197X-2019-63-5-237-244. Russian

18. Zatravkin SN, Vishlenkova EA, Ignatiev VG. The Russian pharmaceutical branch in 1990s. Report 1. From the Soviet to the market. Problems of Social Hygiene, Public Health and History of Medicine. 2022;30(1) 160–6. DOI: 10.32687/0869-866X-2022-30-1-160-166. Russian

19. Zatravkin SN, Vishlenkova EA, Ignatiev VG. The Russian pharmaceutical branch in 1990s. Report II. The optics of external observers. Problems of Social Hygiene, Public Health and History of Medicine. 2022;30(2):322–8. DOI: 10.32687/0869-866X-2022-30-2-322-328. Russian

20. Omelyanovskiy VV, Maksimkina EA, Ivakhnenko OI, Avxentyeva MV, Sura MV, Khachatryan GR. Improvements to the formation of lists of drugs for medical use: analysis of changes in the Government Decree no. 871. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(2):113–23. DOI: 10.17749/2070-4909/farmakoekonomika.2020.032. Russian

21. Voronov DS, Ramenskaya LA. Evaluation of the cost of capital and the discount rate based on the Russian financial statistics. Journal of New Economy. 2023;24(1):50–80. DOI: 10.29141/2658-5081-2023-24-1-3. Russian

22. Trofimova EO, Denisova MN, Utomova AS. Structural changes and import substitution processes in the VZN segment in 2008-2018. Remedium. 2019;(6):14–9. DOI: 10.21518/1561-5936-2019-6-14-19. Russian

23. Grössmann N, Wolf S, Rosian K, Wild C. Pre-reimbursement: early assessment for coverage decisions. Wien Med Wochenschr. 2019;169(11-12):254–62. DOI: 10.1007/s10354-019-0683-1

24. Eriksson I, von Euler M, Malmström RE, Godman B, Wettermark B. Did we see it Coming? An evaluation of the swedish early awareness and alert system. Appl Health Econ Health Policy. 2019;17:93–101. DOI: 10.1007/s40258-018-0434-2

25. Simpson S, Cook A, Miles K. Patient and public involvement in early awareness and alert activities: An example from the United Kingdom. Int J Technol Assess Health Care. 2018;34(1):10–7. DOI: 10.1017/S0266462317004421

26. Gutierrez-Ibarluzea I, Simpson S, Benguria-Arrate G; Members of EuroScan International Network. Early awareness and alert systems: an overview of EuroScan methods. Int J Technol Assess Health Care. 2012;28(3):301–7. DOI: 10.1017/S0266462312000360

27. Wenzl M, Chapman S. Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward. OECD Health Working Papers. 2019;(115). DOI: 10.1787/6e5e4c0f-en

28. Rotar AM, Preda A, Löblová O, Benkovic V, Zawodnik S, Gulacsi L, Niewada M, Boncz I, Petrova G, Dimitrova M, Klazinga N. Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries. Health Policy. 2018;122(3):230–6. DOI: 10.1016/j.healthpol.2018.01.006

29. Zampirolli Dias C, Godman B, Gargano LP, Azevedo PS, Garcia MM, Souza Cazarim M, Pantuzza LLN, Ribeiro-Junior NG, Pereira AL, Borin MC, de Figueiredo Zuppo I, Iunes R, Pippo T, Hauegen RC, Vassalo C, Laba TL, Simoens S, Márquez S, Gomez C, Voncina L, Selke GW, Garattini L, Kwon HY, Gulbinovic J, Lipinska A, Pomorski M, McClure L, Fürst J, Gambogi R, Ortiz CH, Canuto Santos VC, Araújo DV, Araujo VE, Acurcio FA, Alvares-Teodoro J, Guerra-Junior AA. Integrative Review of Managed Entry Agreements: Chances and Limitations. Pharmacoeconomics. 2020;38(11):1165–85. DOI: 10.1007/s40273-020-00943-1